Ceftibuten
Hypersensitivity to penicillins; renal impairment; Porphyria. Monitor renal and haematologic status. Lactation: excretion in milk unknown; use with caution
Respiratory tract infections, Urinary tract infections
Hypersensitivity to cephalosporins.
N/A
1-10% Increased BUN (4%),Nausea (4%),Diarrhea (3%),Headache (3%),Increased eosinophils (3%),Decreased hemoglobin (2%),Dyspepsia (2%),Thrombocytosis (2%),Abdominal pain (1%),Dizziness (1%),Increased ALT (1%),Increased bilirubin (1%),Vomiting (1%) <1% Anorexia,Candidiasis,Constipation,Dysuria,Agitation,Fatigue,Insomnia,Irritability,Paresthesia,Rigors,Diaper rash,Urticaria,Dry mouth,Dyspnea,Nasal congestion,Increased transaminases,Increased creatinine,Leukopenia Potentially Fatal: Pseudomembranous colitis.
Ceftibuten inhibits bacterial cell wall synthesis. It is stable to hydrolysis by many beta-lactamases and has greater activity than 1st or 2nd generation cephalosporins against gm-ve bacteria. It is less active in vitro than cefexime against S. pneumoniae.
Enhanced nephrotoxicity of aminoglycosides. Increased serum concentration w/ probenecid. Decreased serum concentration w/ zinc salts.
Pregnancy Category: B Lactation: excretion in milk unknown; use with caution
Oral Respiratory tract infections, Urinary tract infections Adult: 400 mg once daily for 10 days.
Child: <6 months: Safety and efficacy not established 6-12 years old or <45 kg: 9 mg/kg PO qDay; 400 mg/day PO for 10 days maximum >12 years old or >45 kg: As in adults
Renal impairment: CrCl (ml/min) 30-49 200 mg once daily. 5-29 100 mg once daily.
Susp: Should be taken on an empty stomach. Take 2 hr before or 1 hr after meals. Cap: May be taken with or without food.
Ceftibuten
Hypersensitivity to penicillins; renal impairment; Porphyria. Monitor renal and haematologic status. Lactation: excretion in milk unknown; use with caution
Respiratory tract infections, Urinary tract infections
Hypersensitivity to cephalosporins.
N/A
1-10% Increased BUN (4%),Nausea (4%),Diarrhea (3%),Headache (3%),Increased eosinophils (3%),Decreased hemoglobin (2%),Dyspepsia (2%),Thrombocytosis (2%),Abdominal pain (1%),Dizziness (1%),Increased ALT (1%),Increased bilirubin (1%),Vomiting (1%) <1% Anorexia,Candidiasis,Constipation,Dysuria,Agitation,Fatigue,Insomnia,Irritability,Paresthesia,Rigors,Diaper rash,Urticaria,Dry mouth,Dyspnea,Nasal congestion,Increased transaminases,Increased creatinine,Leukopenia Potentially Fatal: Pseudomembranous colitis.
Ceftibuten inhibits bacterial cell wall synthesis. It is stable to hydrolysis by many beta-lactamases and has greater activity than 1st or 2nd generation cephalosporins against gm-ve bacteria. It is less active in vitro than cefexime against S. pneumoniae.
Enhanced nephrotoxicity of aminoglycosides. Increased serum concentration w/ probenecid. Decreased serum concentration w/ zinc salts.
Pregnancy Category: B Lactation: excretion in milk unknown; use with caution
Oral Respiratory tract infections, Urinary tract infections Adult: 400 mg once daily for 10 days.
Child: <6 months: Safety and efficacy not established 6-12 years old or <45 kg: 9 mg/kg PO qDay; 400 mg/day PO for 10 days maximum >12 years old or >45 kg: As in adults
Renal impairment: CrCl (ml/min) 30-49 200 mg once daily. 5-29 100 mg once daily.
Susp: Should be taken on an empty stomach. Take 2 hr before or 1 hr after meals. Cap: May be taken with or without food.
The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.